CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy.
Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
癌症免疫治疗通过重编程患者自身的免疫系统来根除癌细胞,已在临床上被证明是一种有前景的治疗策略。免疫检查点阻断(ICB)疗法、细胞因子疗法、癌症疫苗和嵌合抗原受体(CAR)T细胞疗法利用免疫治疗技术来缓解肿瘤免疫抑制和/或激活细胞免疫反应,以抑制肿瘤生长、转移和复发。然而,由于免疫治疗药物的非特异性组织分布,全身给药往往受到药物疗效有限和不良反应的阻碍。基于局部支架的递送系统的进步通过创建局部药物储库,促进治疗药物向特定组织部位的控释,通过提高位点特异性疗效和最小化全身毒性,为克服先前免疫治疗的局限性提供了有力策略。在这篇综述中,我们总结了局部支架辅助递送免疫治疗药物以重新教育免疫系统的最新进展,旨在增强抗癌疗效并最小化免疫相关不良事件。此外,还讨论了局部支架辅助癌症免疫治疗在临床转化和应用中的挑战和未来前景。
Cancer immunotherapy, which reprograms a patient's own immune system to eradicate cancer cells, has been demonstrated as a promising therapeutic strategy clinically. Immune checkpoint blockade (ICB) therapies, cytokine therapies, cancer vaccines, and chimeric antigen receptor (CAR) T cell therapies utilize immunotherapy techniques to relieve tumor immune suppression and/or activate cellular immune responses to suppress tumor growth, metastasis and recurrence.
However, systemic administration is often hampered by limited drug efficacy and adverse side effects due to nonspecific tissue distribution of immunotherapeutic agents. Advancements in local scaffold-based delivery systems facilitate a controlled release of therapeutic agents into specific tissue sites through creating a local drug reservoir, providing a potent strategy to overcome previous immunotherapy limitations by improving site-specific efficacy and minimizing systemic toxicity.
In this review, we summarized recent advances in local scaffold-assisted delivery of immunotherapeutic agents to reeducate the immune system, aiming to amplify anticancer efficacy and minimize immune-related adverse events.
Additionally, the challenges and future perspectives of local scaffold-assisted cancer immunotherapy for clinical translation and applications are discussed.
MEMBER ACCOUNT
登录成功会直接打开下一页。